Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 5/20 | 0.52 |
| ▸ | SDC2 | P34741 | 5/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444670 | 1.00 | SDCBP (0.52) | SDCBPSDC2PIK3CGPIK3CDPIK3R1 | |
| SCHEMBL21929926 | 1.00 | SDCBP (0.52) | SDCBPSDC2PIK3CGPIK3CDPIK3R1 | |
| SCHEMBL1500402 | 0.84 | SDCBP (0.50) | SDCBPSDC2UGCG | |
| SCHEMBL1500196 | 0.83 | SDCBP (0.57) | SDCBPSDC2 | |
| SCHEMBL31409592 | 0.83 | CRBN (0.45) | SDCBPSDC2PIK3CGPIK3CDPIK3R1 | |
| SCHEMBL21929871 | 0.81 | SDCBP (0.56) | SDCBPSDC2UGCG | |
| SCHEMBL22020863 | 0.80 | SDCBP (0.44) | SDCBPSDC2UGCG | |
| SCHEMBL21929834 | 0.80 | SDCBP (0.46) | SDCBPSDC2UGCG | |
| SCHEMBL21929904 | 0.78 | SDCBP (0.51) | SDCBPSDC2 | |
| SCHEMBL21929821 | 0.78 | SDCBP (0.54) | SDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| CN-115677692-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-10-27 | — | — | US | disclosed |
| CN-114025756-B | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| CN-114258393-A | Heterocyclic compound with dual phosphatidylinositol 3-kinase delta and gamma inhibitor activity and medical application thereof | 中国医药研究开发中心有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114025756-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102150-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102198-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CG | SDCBP 4550/4885SDC2 4653/4885PIK3CG 3/4885 |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | SDCBP 4626/4885SDC2 4707/4885PIK3CG 4/4885 |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | SDCBP 2018/4885SDC2 2553/4885PIK3CG 3385/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | SDCBP 1614/4885SDC2 2393/4885PIK3CG 2785/4885 |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | SDCBP 4626/4885SDC2 4707/4885PIK3CG 4/4885 |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CG | SDCBP 4618/4885SDC2 4690/4885PIK3CG 3/4885 |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CG | SDCBP 4550/4885SDC2 4653/4885PIK3CG 3/4885 |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | SDCBP 4618/4885SDC2 4690/4885PIK3CG 3/4885 |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CA | SDCBP 4626/4885SDC2 4707/4885PIK3CG 4/4885 |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CA | SDCBP 4626/4885SDC2 4707/4885PIK3CG 4/4885 |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | SDCBP 4618/4885SDC2 4690/4885PIK3CG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.